Barclays
CTXR icon

Barclays’s Citius Pharmaceuticals CTXR Stock Holding History

Barclays’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$663 Buy
+1,096
New +$742 ﹤0.01% 4970
2025
Q2 		– Sell
-29
Closed -$43 – 5314
2025
Q1 		$43 Buy
+29
New +$69 ﹤0.01% 5150
2024
Q4 		– Hold
0
– -$1 – 5311
2024
Q3 		– Sell
-1,513
Closed -$25.5K – 5261
2024
Q2 		$22.1K Sell
1,513
-2,266
-60% -$40.6K ﹤0.01% 4423
2024
Q1 		$84.8K Sell
3,779
-2,974
-44% -$54.3K ﹤0.01% 4491
2023
Q4 		$128K Buy
6,753
+5,882
+675% +$112K ﹤0.01% 4573
2023
Q3 		$14.9K Sell
871
-109
-11% -$2.59K ﹤0.01% 4234
2023
Q2 		$29.4K Buy
+980
New +$32.3K ﹤0.01% 4044
2022
Q4 		– Sell
-135
Closed -$4K – 5283
2022
Q3 		$4K Sell
135
-129
-49% -$3.54K ﹤0.01% 4530
2022
Q2 		$6K Sell
264
-540
-67% -$14.8K ﹤0.01% 4744
2022
Q1 		$36K Sell
804
-4,709
-85% -$186K ﹤0.01% 4237
2021
Q4 		$212K Buy
5,513
+3,657
+197% +$166K ﹤0.01% 3543
2021
Q3 		$94K Sell
1,856
-247
-12% -$12.4K ﹤0.01% 3923
2021
Q2 		$183K Buy
2,103
+1,729
+462% +$104K ﹤0.01% 3595
2021
Q1 		$17K Buy
+374
New +$14.9K ﹤0.01% 4393
2020
Q1 		– Hold
0
– – – 6185
2019
Q4 		– Hold
0
– – – 6413

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MFS
Miller Financial Services Marshall, Michigan $124M AUM 17.62% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM

Barclays's CTXR Position: Q2 2026 in Review

Barclays opened a new position in Citius Pharmaceuticals (CTXR) in Q2 2026: 1,096 shares worth $663. The stake represents ﹤0.01% of the portfolio and ranks #4970 among its holdings. This is a return to the name: Barclays previously reported a position in CTXR as recently as Q1 2025.

Barclays first reported a position in CTXR in Q1 2021 and has held it in 14 quarters since. The position peaked at $212K in Q4 2021. 43 funds tracked by Wall St. Rank hold CTXR as of Q2 2026.

  • Barclays held 1,096 shares of Citius Pharmaceuticals worth $663 as of Q2 2026.
  • Citius Pharmaceuticals was a new Barclays position in Q2 2026.
  • Citius Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4970 holding.
  • Barclays first reported a position in Citius Pharmaceuticals in Q1 2021 and has held it in 14 quarters since.
  • Barclays's Citius Pharmaceuticals position peaked at $212K in Q4 2021.
  • 43 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.